GRI Bio discusses positive Phase 2a IPF data for GRI-0621
GRI Bio discussed positive Phase 2a idiopathic pulmonary fibrosis data for GRI-0621, highlighting biomarker results indicating improvements in fibrosis and lung repair.
IPF
DiseaseDisease Profile
IPF (idiopathic pulmonary fibrosis) is a chronic, progressive interstitial lung disease characterized by increasing fibrosis that impairs oxygen transfer. It generally affects older adults and can lead to progressive respiratory failure.
- Category
- interstitial lung disease
- Prevalence
- Estimated prevalence is 13 to 20 per 100,000 people worldwide; about 100,000 people are affected in the United States.
Related News
Deupirfenidone Advances to Phase 3 Trial for Idiopathic Pulmonary Fibrosis
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
Deupirfenidone Receives Orphan Drug Designation from FDA and European Commission for IPF
PureTech Health announced that deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for idiopathic pulmonary fibrosis, with a Phase 3 trial planned for the first half of 2026.
PureTech's Deupirfenidone Receives FDA and EU Orphan Drug Designation for IPF
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
AbbVie Advances Clinical Pipeline With IPF and Aesthetics Trial Updates
AbbVie reported progress on two clinical studies: a Phase 2a trial of ABBV-142 for idiopathic pulmonary fibrosis now recruiting patients, and completion of a JUVÉDERM VOLITE study for facial skin quality improvement.
Three Clinical Trial Pipeline Reports Track Progress in Prostate Cancer, NK Cells, and Lung Diseases
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
AI Adoption in Clinical Trials Focuses on Operations, Drug Discovery, and Patient Engagement
Artificial intelligence emerged as the dominant topic in clinical research during 2025, with applications spanning operational efficiency, drug discovery, and patient recruitment, though no AI-discovered drug has yet achieved FDA marketing approval.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07528703 |
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07519070 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07493031 |
A PhaseⅠ Study of HW252001 in Healthy Subjects |
NOT_YET_RECRUITING | PHASE1 |
| NCT07448194 |
A Phase Ia Clinical Trial of HW241045 |
RECRUITING | PHASE1 |
| NCT07169253 |
Prognostic Score Comparison in IPF and HP |
COMPLETED | |
| NCT07139925 |
Assessment of Self-Care in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
ACTIVE_NOT_RECRUITING | |
| NCT07031362 |
The Effectiveness of Pulmonary Rehabilitation on Saturation in Patients With Idiopathic Pulmonary Fibrosis |
COMPLETED | NA |
| NCT06747923 |
SB17170 Phase 2 Trial in IPF Patients |
RECRUITING | PHASE2 |
| NCT06714812 |
Diarrheal Adverse Events in Caucasian Patients With Idiopathic Pulmonary Fibrosis Undergoing Treatment With Nintedanib |
ACTIVE_NOT_RECRUITING | |
| NCT06714188 |
Application of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis |
COMPLETED |